Investigational Drug Information for PF-05221304
✉ Email this page to a colleague
What is the development status for investigational drug PF-05221304?
PF-05221304 is an investigational drug.
There have been 11 clinical trials for PF-05221304.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 22nd 2017.
The most common disease conditions in clinical trials are Liver Diseases, Non-alcoholic Fatty Liver Disease, and Fatty Liver. The leading clinical trial sponsors are Pfizer, Columbia University, and Henry N. Ginsberg.
There are two US patents protecting this investigational drug and forty-two international patents.
Summary for PF-05221304
| US Patents | 2 |
| International Patents | 42 |
| US Patent Applications | 22 |
| WIPO Patent Applications | 11 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 2 (2017-08-22) |
| Vendors | 21 |
Recent Clinical Trials for PF-05221304
| Title | Sponsor | Phase |
|---|---|---|
| Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism | Pfizer | Phase 1 |
| Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism | Columbia University | Phase 1 |
| Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism | Henry N. Ginsberg | Phase 1 |
Clinical Trial Summary for PF-05221304
Top disease conditions for PF-05221304
Top clinical trial sponsors for PF-05221304
US Patents for PF-05221304
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-05221304 | ⤷ Sign Up | GLP-1 receptor agonists and uses thereof | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| PF-05221304 | ⤷ Sign Up | GLP-1 receptor agonists and uses thereof | Pfizer Inc. (New York, NY) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-05221304
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-05221304 | Canada | CA2811033 | 2030-09-30 | ⤷ Sign Up |
| PF-05221304 | Cyprus | CY1118016 | 2030-09-30 | ⤷ Sign Up |
| PF-05221304 | Denmark | DK2621493 | 2030-09-30 | ⤷ Sign Up |
| PF-05221304 | European Patent Office | EP2621493 | 2030-09-30 | ⤷ Sign Up |
| PF-05221304 | Spain | ES2602111 | 2030-09-30 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
